107367-98-6

Basic information

• Product Name: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID
• Synonyms: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID;(5-METHYL-2-PHENYLOXAZOL-4-YL)ACETIC ACID;BUTTPARK 37\06-80;(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID;2-(5-Methyl-2-phenyl-oxazol-4-yl)-acetic acid
• CAS NO: 107367-98-6
• Molecular Formula: C₁₂H₁₁NO₃
• Molecular Weight: 217.22
• Product Categories: Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles;Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles
• Mol File: 107367-98-6.mol

Chemical Properties

• Melting Point: 131 °C
• Boiling Point: 411.7 °C at 760 mmHg
• Flash Point: 202.8 °C
• Appearance: /
• Density: 1.245 g/cm³
• Vapor Pressure: 1.63E-07mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• PKA: 3.80±0.10(Predicted)
• CAS DataBase Reference: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID(107367-98-6)
• EPA Substance Registry System: 2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ACETIC ACID(107367-98-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 107367-98-6(Hazardous Substances Data)

Usage

Uses

Given the limited information on the specific applications of 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetic acid, the following uses are inferred based on the general utility of oxazole-containing compounds in the pharmaceutical and chemical industries:
Used in Pharmaceutical Industry:
2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetic acid is used as a building block or intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs with diverse therapeutic benefits. The presence of the oxazole ring may enhance the compound's bioactivity, making it a valuable component in medicinal chemistry.
Used in Chemical Research:
In the field of chemical research, 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetic acid serves as a subject for investigation to explore its physical and chemical properties, as well as its reactivity with other compounds. Understanding these properties can lead to the discovery of new reactions or applications in organic synthesis.
Used in Bioactive Compounds Development:
2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetic acid is utilized as a key structural element in the design and synthesis of bioactive compounds, potentially leading to the creation of novel agents with applications in various therapeutic areas, given the known importance of oxazoles in natural and synthetic bioactive molecules.

InChI:InChI=1/C12H11NO3/c1-8-10(7-11(14)15)13-12(16-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3,(H,14,15)

Upstream product

• 103788-64-3 methyl 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetate 
• 27492-46-2 4,5-dimethyl-2-phenyl-oxazole 3-oxide 
• 100-52-7 benzaldehyde 
• 98-88-4 benzoyl chloride 
• 258346-54-2 3-(5-methyl-2-phenyl-4-oxazolyl)propionitrile 
• 186895-16-9 5-Methyl-4-hydroxyethyl-2-phenyl-oxazole 
• 100373-13-5 methyl 3-benzamido-4-oxovalerate 
• 54819-26-0 methyl 3-(benzoylamino)-4-oxovalerate 
• 39741-26-9 N-benzoyl-L-aspartic acid β-methyl ester 
• 103788-61-0 (5-methyl-2-phenyl-4-oxazolyl)methyl chloride 
• 524959-64-6 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetonitrile 

Downstream Products

• 103788-65-4 (5-methyl-2-phenyloxazol-4-yl)ethanol 
• 851179-99-2 3-methoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazole-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-94-7 3-ethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-99-2 3-methoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-pentanoic acid methyl ester 
• 932024-95-8 2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-3-propoxyimino-butyric acid methyl ester 
• 932025-00-8 3-ethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-pentanoic acid methyl ester 
• 932024-96-9 3-isobutoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-98-1 3-cyclopropylmethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-97-0 3-butoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 

Relevant articles and documents

Design and synthesis of Oxime ethers of β-oxo-γ-phenylbutanoic acids as PPAR a and -γ dual agonists

Oxime ethers of p-oxo-y-phenylbutanoic acids were prepared to develop more effective PPAR a and y dual agonists. Among them, compound 11k exhibited potent in vitro activities with EC50 of 2.5 nM and 3.3 nM in PPAR a and y, respectively. It showed better g

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Design, synthesis, and SAR of novel α-alkoxy-β-arylpropionic acids as potent and balanced PPARαγ coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.

Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists

Oxime ethers of α-acyl-β-phenylpropanoic acids were prepared to apply as PPARα and γ dual agonists. Among them, compound 11l proved to exhibit potent in vitro activities with EC50 of 19 and 13 nM in PPARα and γ, respectively. It showed better g

Conversion of human-selective PPARα agonists to human/mouse dual agonists: A molecular modeling analysis

To understand the species selectivity in a series of α-methyl- α-phenoxy carboxylic acid PPARα/γ dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARα. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARα leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARα agonist to a human and mouse dual agonist within the same platform.

Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.

Antidiabetic agents

The present invention provides compounds of Formula (I): wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.

Oxazolidinedione hypoglycemic agents

Compounds of the formulae STR1 where R is cycloalkyl or aryl; R1 is alkyl, X is O or C=O; A is O or S; and B is N or CH are useful as hypoglycemic agents.

Thiazolidinedione derivatives as hypoglycemic agents

Hypoglycemic thiazolidine-2,4-dione derivatives of the formula STR1 wherein the dotted line represents a bond or no bond; V is --CH=CH--, --N=CH--, --CH=N--, S, O or NR; W is S, SO, SO2, SO2 NR1, NR1 SO2/s

Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents

A new series of thiazolidine-2,4-diones was obtained by replacing the ether function of englitazone with various functional groups, i.e., a ketone, alcohol, or olefin moiety.These compounds lower blood glucose levels in the genetically obese and insulin-r

Oxazolidinedione hypoglycemic agents

Compounds of the formulae where R is cycloalkyl or aryl; R1 is alkyl, X is O or C=O; A is O or S; and B is N or CH are useful as hypoglycemic agents.